PIK3CA mutation	HER2 Negative Breast Cancer	PIK3CA mutation	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	RG7440 Resistant: B - Late Trials RG7440 Resistant : B	RG7440 Resistant: B - Late Trials RG7440 Resistant : B
PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	panitumumab Resistant: B - Late Trials panitumumab Resistant : B	panitumumab Resistant: B - Late Trials panitumumab Resistant : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	neratinib Resistant: B - Late Trials neratinib Resistant : B	neratinib Resistant: B - Late Trials neratinib Resistant : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	lapatinib Resistant: B - Late Trials lapatinib Resistant : B	lapatinib Resistant: B - Late Trials lapatinib Resistant : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B
PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	everolimus Sensitive: B - Late Trials everolimus Sensitive : B	everolimus Sensitive: B - Late Trials everolimus Sensitive : B
PIK3CA mutation	Non Small Cell Lung Cancer	PIK3CA mutation	Non Small Cell Lung Cancer	erlotinib Resistant: B - Late Trials erlotinib Resistant : B	erlotinib Resistant: B - Late Trials erlotinib Resistant : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab + pertuzumab + alpelisib Sensitive: B - Late Trials trastuzumab + pertuzumab + alpelisib Sensitive : B	trastuzumab + pertuzumab + alpelisib Sensitive: B - Late Trials trastuzumab + pertuzumab + alpelisib Sensitive : B

PIK3CA mutation

Associations